Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $35.5 million.

  • Voyager Therapeutics' Total Current Liabilities fell 1971.27% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.5 million, marking a year-over-year decrease of 1971.27%. This contributed to the annual value of $49.8 million for FY2024, which is 2281.89% down from last year.
  • Voyager Therapeutics' Total Current Liabilities amounted to $35.5 million in Q3 2025, which was down 1971.27% from $42.0 million recorded in Q2 2025.
  • Voyager Therapeutics' Total Current Liabilities' 5-year high stood at $101.7 million during Q1 2022, with a 5-year trough of $19.9 million in Q1 2023.
  • Its 5-year average for Total Current Liabilities is $52.0 million, with a median of $45.4 million in 2023.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 31079.96% in 2022, then crashed by 8038.99% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Total Current Liabilities stood at $51.0 million in 2021, then skyrocketed by 42.39% to $72.6 million in 2022, then dropped by 11.13% to $64.5 million in 2023, then dropped by 22.82% to $49.8 million in 2024, then dropped by 28.71% to $35.5 million in 2025.
  • Its last three reported values are $35.5 million in Q3 2025, $42.0 million for Q2 2025, and $40.2 million during Q1 2025.